Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2495-2502

  Reist, Craig J ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CHIMERA; DISULFIDE BOND; GLIOMA; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIODINATION; TISSUE DISTRIBUTION; TISSUE HOMOGENATE;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG STABILITY; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN G; IODINE RADIOISOTOPES; MICE; MOLECULAR WEIGHT; QUALITY CONTROL; RECOMBINANT FUSION PROTEINS; TENASCIN; TISSUE DISTRIBUTION;

EID: 0031755178     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bourdon, M. A., Wikstrand, C. J., Furthmayr, H., Matthews, T. J., and Bigner, D. D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res., 43: 2796-2805, 1983.
2. Howeedy, A. A., Virtanen, I., Laitinen, L., Gould, N. S., Koukoulis, G. K., and Gould, V. E. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab. Invest., 63: 798-806. 1990.
3. Mackie, E. J., Chiquet-Ehrismann, R., Pearson, C. A., Inaguma, Y., Taya, K., Kawarada, Y., and Sakakura, T. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc. Natl. Acad. Sci. USA, 84: 4621-4625, 1987.
4. 2-a preliminary report. J. Neurooncol. 24: 109-122, 1995.
5. 131I-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin. Cancer Res., 2; 963-972, 1996.
6. Bigner, D. D., Brown, M. T., Friedman, A. H., Coleman, R. E., Akabani, G., Friedman, H. S., Thorstad, W. L., McLendon, R. E., Bigner, S. H., Zhao, X-G., Pegram, C. N., Wikstrand, C. J., Herndon, J. E., II, Vick, N. A., Paleologos, N., Cokgor, I., and Zalutsky, M. R. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol., 16: 2202-2212, 1998.
7. He, X., Archer, G. E., Wikstrand, C. J., Morrison, S. L., Zalutsky, M. R., Bigner, D. D., and Batra, S. K. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J. Neuroimmunol., 52: 127-137, 1994.
8. Shin. S-U. Chimeric antibody: potential applications for drug delivery and immunotherapy. Biotherapy, 3: 43-53, 1991.
9. Colcher, D., Milenic, D., Roselli, M., Raubitschek, A., Yarranton, G., King, D., Adair, J., Whittle, N., Bodmer, M., and Schlom, J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res., 49: 1738-1745, 1989.
10. Brown, B. A., Davis, G. L., Saltzgaber-Muller, J., Simon, P., Ho, M-K., Shaw, P. S., Stone, B. A., Sands, H., and Moore, G. P. Tumor-specific genetically engineered murine/human chimeric monoclonal antibody. Cancer Res., 47: 3577-3583, 1987.
11. Saga, T., Endo, K., Koizumi, M., Kawamura, Y., Watanabe, Y., Konishi, J., Ueda, R., Nishimura, Y., Yokoyama, M., and Watanabe, T. In vitro and in vivo properties of human/mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. J. Nucl. Med., 31: 1077-1083, 1989.
12. Sahagan, B. G., Dorai, H., Saltzgaber-Muller, J., Toneguzzo, F., Guindon, C. A., Lilly, S. P., McDonald, K. W., Morrisey, D. V., Stone, B. A., Davis, G. L., McIntosh, P. K., and Moore, G. P. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J. Immunol., 137: 1066-1074, 1986.
13. Molthoff, C. F., Buist, M. R., Kenemans, P., Pinedo, H. M., and Boven, E. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody. MOv18, reactive with an ovarian cancer-associated antigen. J. Nucl. Med., 33: 2000-2005, 1992.
14. Goodman, G. E., Hellstrom, I., Yelton, D. E., Murray, J. L., O'Hara, S., Meaker, E., Zeigler, L., Palazollo, P., Nicaise, C., Usakewicz, J., and Hellstrom, K. E. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer. Immunol. Immunother., 36: 267-273, 1993.
15. Novak-Hofer, I., Amstutz, H. P., Haldemann, A., Blaser, K., Morgenthaler, J. J., Blauenstein, P., and Schubiger, P. A. Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7. J. Nucl. Med., 33: 231-236, 1992.
16. Gillies, S. D., and Wesolowski, J. S. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum. Antib. Hybrid., 1: 47-54, 1990.
17. Zalutsky, M. R., Archer, G. E., Garg, P. K., Batra, S. K., and Bigner, D. D. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl. Med. Biol., 23: 449-458, 1996.
18. Zalutsky, M. R., Noska, M. A., Colapinto, E. V., Garg, P. K., and Bigner, D. D. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res., 49: 5543-5549, 1989.
19. Morelock, M. M., Rothlein, R., Bright, S. M., Robinson, M. K., Graham, E. T., Sabo, J. P., Owens, R., King, D. J., Norris, S. H., Scher, D. S., Wright, J. L., and Adair, J. R. Isotype choice for chimeric antibodies affects binding properties. J. Biol. Chem., 269; 13048-13055, 1994.
20. Batra, S. K., Niswonger, M. L., Wikstrand, C. J., Pegram, C. N., Zalutsky, M. R., Morrison, S. L., and Bigner, D. D. Mouse/human chimeric Mel-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Hybridoma. 13: 87-97, 1994.
21. Reist, C. J., Batra, S. K., Pegram, C. N., Bigner, D. D., and Zalutsky, M. R. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl. Med. Biol., 24: 639-647, 1997.
22. 2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. Bioconj. Chem., 6: 493-501, 1995.
23. Dumas, P. Deshalogenation de divers deries iodes phenoliques chez le rat normal et thyroidectomise. Biochem. Pharmacol., 22: 1599-1605. 1979.
24. Nisonoff, A., Hopper, J. E., and Spring, S. B. The Antibody Molecule, pp. 92-337. New York: Academic Press, 1975.
25. Yamaguchi, Y., Kim, H. H., Kato, K., Masuda, K., Shimada, I., and Arata, Y. Proteolytic fragmentation with high specificity of mouse immunoglobulin G: mapping a proteolytic cleavage sites in the hinge region. J. Immunol. Methods, 181: 259-267, 1995.
26. Vieira, P., and Rajewsky, K. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol., 18: 313-316, 1988.
27. Pollock, R. R., French, D. L., Metlay, J. P., Birshtein, B. K., and Scharff, M. D. Intravascular metabolism of normal and mutant mouse immunoglobulin molecules. Eur. J. Immunol., 20: 2021-2027, 1990.
28. γ3 homology regions of human immunoglobulin G. J. Immunol., 116: 518-526, 1976.
29. 1 in the circulation of mice. Scand. J. Immunol., 40: 457-465, 1994.
30. Kim, J. K., Tsen, M. F., Ghetie, V., and Ward, E. S. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur. I. Immunol., 24: 2429-2434, 1994.
31. Brambell, F. W. R., Hemmings, W. A., and Morris, I. G. A theoretical model of gamma-globulin catabolism. Nature (Lond.), 203: 1352-1355, 1964.
32. Tao, M-H., and Morrison, S. L. Studies of aglycosylated chimeric mouse-human IgG: role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol., 143: 2595-2601, 1989.
33. 4 subclass in vivo. Int. J. Cancer, 50: 416-422, 1992.
34. Brekke, O. H., Michaelsen, T. E., and Sandlie, I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol, Today. 16: 85-89, 1995.
35. Dangl, J. L., Wensel, T. G., Morrison, S. L., Stryer, L., Herzenberg, L. A., and Oi, V. T. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J., 7: 1989-1994, 1994.